206 related articles for article (PubMed ID: 16367943)
1. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.
Mitsuyama K; Tomiyasu N; Suzuki A; Takaki K; Takedatsu H; Masuda J; Yamasaki H; Matsumoto S; Tsuruta O; Toyonaga A; Sata M
Clin Exp Immunol; 2006 Jan; 143(1):125-31. PubMed ID: 16367943
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.
Mitsuyama K; Toyonaga A; Sasaki E; Ishida O; Ikeda H; Tsuruta O; Harada K; Tateishi H; Nishiyama T; Tanikawa K
Gut; 1995 Jan; 36(1):45-9. PubMed ID: 7890234
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
Nikolaus S; Waetzig GH; Butzin S; Ziolkiewicz M; Al-Massad N; Thieme F; Lövgren U; Rasmussen BB; Reinheimer TM; Seegert D; Rosenstiel P; Szymczak S; Schreiber S
Int J Colorectal Dis; 2018 Jul; 33(7):927-936. PubMed ID: 29748708
[TBL] [Abstract][Full Text] [Related]
4. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease.
Bross DA; Leichtner AM; Zurakowski D; Law T; Bousvaros A
J Pediatr Gastroenterol Nutr; 1996 Aug; 23(2):164-71. PubMed ID: 8856584
[TBL] [Abstract][Full Text] [Related]
5. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia.
Wang Y; Lewis DF; Gu Y; Zhao S; Groome LJ
Hypertension; 2011 Feb; 57(2):336-42. PubMed ID: 21173340
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
7. Mucosal Immunity Related to FOXP3
Cho J; Kim S; Yang DH; Lee J; Park KW; Go J; Hyun CL; Jee Y; Kang KS
J Korean Med Sci; 2018 Dec; 33(52):e336. PubMed ID: 30584414
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.
Naftali T; Novick D; Gabay G; Rubinstein M; Novis B
Isr Med Assoc J; 2007 Jul; 9(7):504-8. PubMed ID: 17710779
[TBL] [Abstract][Full Text] [Related]
9. The circulating common gamma chain (CD132) in inflammatory bowel disease.
Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
[TBL] [Abstract][Full Text] [Related]
10. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis.
Mahida YR; Kurlac L; Gallagher A; Hawkey CJ
Gut; 1991 Dec; 32(12):1531-4. PubMed ID: 1773961
[TBL] [Abstract][Full Text] [Related]
11. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia.
Zhang Z; Gao Y; Zhang L; Jia L; Wang P; Zhang L; Li H
Hypertens Pregnancy; 2013 Aug; 32(3):270-80. PubMed ID: 23782174
[TBL] [Abstract][Full Text] [Related]
12. IL-6 Transsignaling in Patients with Chronic Spontaneous Urticaria.
Kasperska-Zajac A; Grzanka A; Damasiewicz-Bodzek A
PLoS One; 2015; 10(12):e0145751. PubMed ID: 26699882
[TBL] [Abstract][Full Text] [Related]
13. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
14. Immune system alterations in patients with inflammatory bowel disease during remission.
Sventoraityte J; Zvirbliene A; Kiudelis G; Zalinkevicius R; Zvirbliene A; Praskevicius A; Kupcinskas L; Tamosiūnas V
Medicina (Kaunas); 2008; 44(1):27-33. PubMed ID: 18277086
[TBL] [Abstract][Full Text] [Related]
15. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.
Pignatti P; Ciapponi L; Galle P; Hansen MB; Massa M; Meazza C; Paonessa G; Novick D; Ciliberto G; Martini A; De Benedetti F
Clin Exp Immunol; 2003 Feb; 131(2):355-63. PubMed ID: 12562400
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity.
Nancey S; Hamzaoui N; Moussata D; Graber I; Bienvenu J; Flourie B
Dig Dis Sci; 2008 Jan; 53(1):242-7. PubMed ID: 17549633
[TBL] [Abstract][Full Text] [Related]
17. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
18. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease.
Nielsen OH; Langholz E; Hendel J; Brynskov J
Dig Dis Sci; 1994 Sep; 39(9):1918-23. PubMed ID: 7521822
[TBL] [Abstract][Full Text] [Related]
19. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells.
Mueller C; Knoflach P; Zielinski CC
Gastroenterology; 1990 Mar; 98(3):639-46. PubMed ID: 2298368
[TBL] [Abstract][Full Text] [Related]
20. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130.
Yasukawa K; Futatsugi K; Saito T; Yawata H; Narazaki M; Suzuki H; Taga T; Kishimoto T
Immunol Lett; 1992 Feb; 31(2):123-30. PubMed ID: 1740350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
